ES2196559T3 - Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer. - Google Patents

Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer.

Info

Publication number
ES2196559T3
ES2196559T3 ES98921688T ES98921688T ES2196559T3 ES 2196559 T3 ES2196559 T3 ES 2196559T3 ES 98921688 T ES98921688 T ES 98921688T ES 98921688 T ES98921688 T ES 98921688T ES 2196559 T3 ES2196559 T3 ES 2196559T3
Authority
ES
Spain
Prior art keywords
inhibitors
cancer treatment
transferasa
farnesil
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98921688T
Other languages
English (en)
Inventor
Shama Mohammed Kajiji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2196559T3 publication Critical patent/ES2196559T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un procedimiento relativo al tratamiento anticanceroso en un mamífero, y en particular a los humanos, y que consiste a administrar, a este mamífero, un inhibidor de FTasa asociado a un inhibidor de HMG CoA reductasa.
ES98921688T 1997-06-16 1998-06-05 Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer. Expired - Lifetime ES2196559T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
ES2196559T3 true ES2196559T3 (es) 2003-12-16

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98921688T Expired - Lifetime ES2196559T3 (es) 1997-06-16 1998-06-05 Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer.

Country Status (37)

Country Link
EP (1) EP0986387B1 (es)
JP (1) JP3713051B2 (es)
KR (1) KR100392573B1 (es)
CN (1) CN1259868A (es)
AP (1) AP9801261A0 (es)
AR (1) AR013090A1 (es)
AT (1) ATE235905T1 (es)
BG (1) BG103946A (es)
BR (1) BR9810616A (es)
CA (1) CA2294399C (es)
CO (1) CO4950607A1 (es)
DE (1) DE69812933T2 (es)
DK (1) DK0986387T3 (es)
DZ (1) DZ2518A1 (es)
EA (1) EA199901043A1 (es)
ES (1) ES2196559T3 (es)
GT (1) GT199800081A (es)
HN (1) HN1998000091A (es)
HR (1) HRP980328B1 (es)
HU (1) HUP0004624A3 (es)
ID (1) ID23014A (es)
IL (1) IL132765A0 (es)
IS (1) IS5259A (es)
MA (1) MA24569A1 (es)
NO (1) NO996206L (es)
NZ (1) NZ500662A (es)
OA (1) OA11231A (es)
PA (1) PA8453601A1 (es)
PE (1) PE82899A1 (es)
PL (1) PL337651A1 (es)
PT (1) PT986387E (es)
SK (1) SK169699A3 (es)
TN (1) TNSN98088A1 (es)
TR (1) TR199903074T2 (es)
UA (1) UA57081C2 (es)
WO (1) WO1998057633A1 (es)
ZA (1) ZA985182B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077949A2 (en) 1998-05-12 2001-02-28 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU7445998A (en) 1999-01-04
AU724676B2 (en) 2000-09-28
CO4950607A1 (es) 2000-09-01
JP3713051B2 (ja) 2005-11-02
PL337651A1 (en) 2000-08-28
KR20010013839A (ko) 2001-02-26
DE69812933D1 (de) 2003-05-08
ZA985182B (en) 1999-12-17
EP0986387A1 (en) 2000-03-22
HUP0004624A2 (hu) 2001-10-28
PA8453601A1 (es) 2000-05-24
HRP980328A2 (en) 1999-04-30
HRP980328B1 (en) 2002-06-30
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
DZ2518A1 (fr) 2003-02-01
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
PT986387E (pt) 2003-06-30
DK0986387T3 (da) 2003-07-14
IL132765A0 (en) 2001-03-19
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
TNSN98088A1 (fr) 2005-03-15
NO996206L (no) 2000-02-15
ATE235905T1 (de) 2003-04-15
SK169699A3 (en) 2000-06-12
DE69812933T2 (de) 2003-11-06
WO1998057633A1 (en) 1998-12-23
IS5259A (is) 1999-11-19
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
NZ500662A (en) 2001-10-26
AR013090A1 (es) 2000-12-13
BG103946A (bg) 2000-07-31
EP0986387B1 (en) 2003-04-02
GT199800081A (es) 1999-12-07
TR199903074T2 (xx) 2000-05-22
ID23014A (id) 1999-12-30
KR100392573B1 (ko) 2003-07-23
OA11231A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
UY26092A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
ES2196559T3 (es) Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer.
CY1119339T1 (el) Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος
CY1107285T1 (el) ΣΥΝΔΥΑΣΜΟΙ ΑΠΟΤΕΛΟΥΜΕΝΟΙ ΑΠΟ ΑΝΑΣΤΟΛΕΙΣ cGMP PDE5
BRPI0411437A (pt) stents
CO6331446A2 (es) Composiciones farmaceúticas que comprenden la combinación de un agente antimitotico y un compuesto inhibidor de aurora quinasa, utiles en el tratamiento anticancerígeno
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
SV2009003227A (es) Composiciones de inhibidores de chk 1 ref. x-17672
CY1107545T1 (el) Μεθοδοι για την προκληση θανατου καρκινικων κυτταρων και υποχωρησης του ογκου
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
SV2002000761A (es) Pirrolo [2.1-a]dihidroisoquinolinas ref. lea 35090-sv
CO5180597A1 (es) Composiciones anhidras utiles como filtros para rayos ultra violeta con un factor de proteccion solar alto
BR0114430A (pt) Processos para a indução da morte de células cancerìgenas e para a regressão de tumor
UY29774A1 (es) Inhibidor de atm
CL2023003604A1 (es) Conjugados de neodegradadores
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
ES2174297T3 (es) Nuevos derivados de piranosidos.
BR0308587A (pt) Uso de rapamicina para inibir a morte de células
AR011476A1 (es) Nitrometilcetonas, su procedimiento de preparacion, composiciones que las contienen y su utilizacion para preparar medicamentos.
BR0317052A (pt) Composto, métodos para tratar câncer ou doença neoplástica e uma infecção fúngica, para inibir o desenvolvimento de uma célula cancerosa ou célula neoplástica e de um fungo e para induzir a citotoxicidade em uma célula cancerosa ou célula neoplástica, e, composição
MX9300268A (es) Nuevas 4-cinolinil-y 4-naftiridinil-dihidropiridinas, procedimiento para su obtencion y medicamentos que las contienen.
ECSP982539A (es) INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCER